Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody
Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody
Molecular Therapy 24,
1634 (september 2016). doi:10.1038/mt.2016.141
Authors: Ursula Jördis Eva Seidel, Patrick Schlegel, Ludger Grosse-Hovest, Martin Hofmann, Steffen Aulwurm, Elwira Pyz, Friedhelm R Schuster, Roland Meisel, Martin Ebinger, Tobias Feuchtinger, Heiko-Manuel Teltschik, Kai-Erik Witte, Carl-Philipp Schwarze, Hans-Georg Rammensee, Rupert Handgretinger, Gundram Jung & Peter Lang
Source: Molecular Therapy - Category: Genetics & Stem Cells Authors: Ursula J ördis Eva Seidel Patrick Schlegel Ludger Grosse-Hovest Martin Hofmann Steffen Aulwurm Elwira Pyz Friedhelm R Schuster Roland Meisel Martin Ebinger Tobias Feuchtinger Heiko-Manuel Teltschik Kai-Erik Witte Carl-Philipp Schwarze Hans-Georg Rammense Source Type: research